A 36-Month Study on the Cost/Utility of Add-On Omalizumab in Persistent Difficult-to-Treat Atopic Asthma in Italy

Abstract

The 36-month add-on omalizumab therapy persistently improved all clinical outcomes in difficult-to-treat asthmatic patients. Costs were also optimized and related to the extent of long-term health benefits achieved.